Related Experiment Video
Updated: Jul 14, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Treatment of experimental myocarditis via modulation of the renin-angiotensin system
Melvin D Daniels1, Kenneth V Hyland, David M Engman
1Department of Pathology and Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. d-engman@northwestern.edu
Insights
Drugs targeting the renin-angiotensin system, like ACE inhibitors and ARBs, show promise for treating myocarditis. They reduce inflammation and fibrosis without broad immune suppression, aiding recovery from heart inflammation.
Area of Science:
- Cardiovascular Research
- Immunology
- Pharmacology
Background:
- The renin-angiotensin system regulates vascular tone and is targeted by drugs for hypertension and cardiomyopathy.
- Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor antagonists (ARBs) also impact inflammation, adhesion molecules, and fibrosis.
- Myocarditis, an inflammatory heart condition, presents a potential therapeutic target for these agents.
Purpose of the Study:
- To review the efficacy of ACEIs and ARBs in experimental models of infectious and autoimmune myocarditis.
- To assess the therapeutic potential of renin-angiotensin system modulation for inflammatory heart disease.
Main Methods:
- Review of studies using mouse models of virus-induced myocarditis.
- Review of studies using mouse models of parasite-induced myocarditis.
- Review of studies using mouse models of autoimmune cardiomyopathy.
Main Results:
- ACEIs and ARBs demonstrate efficacy in treating various forms of experimental myocarditis.
- These drugs modulate key inflammatory and fibrotic pathways in the heart.
- Renin-angiotensin modulation appears to downregulate autoimmunity without causing detrimental immune suppression.
Conclusions:
- Evidence strongly supports using renin-angiotensin modulation for myocarditis treatment.
- This approach offers a potential strategy for managing inflammatory heart diseases.
- Therapeutic benefits include reduced inflammation and fibrosis with preserved immune function.
Abstract:
The renin-angiotensin system is primarily responsible for regulating vascular tone. Drugs that inhibit this pathway, angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists, are widely used to treat hypertension and a variety of cardiomyopathies. Recent studies have shown that, in addition to reducing blood pressure, these drugs also modulate inflammation, adhesion molecule expression, and fibrosis. To assess the therapeutic potential of these inhibitory agents for the treatment of inflammatory heart disease, the drugs have been tested in experimental models of infectious and autoimmune myocarditis. This review summarizes the results of studies examining the efficacy of angiotensin converting enzyme inhibitors and angiotensin receptor antagonists for the treatment of mouse models of virus-induced and parasite-induced myocarditis, as well as autoimmune cardiomyopathy. The collective results strongly support the use of renin-angiotensin modulation for the treatment of myocarditis. Importantly, this therapeutic approach seems to downregulate autoimmunity without causing immune suppression which may enhance the survival of the disease-initiating infectious agent.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Myocarditis III: Medical Management
Antihypertensive Drugs: Direct Renin Inhibitors
Myocarditis IV: Nursing Management
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Cardiomyopathy V: Interprofessional Care
